Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC

Journal of Biomedical Science

Minwen Ha²  Yanyun Wang²  Jian Cheng²  Yue Wang²  Yadi Wang¹  Xia Wang² 

[1] Department of Oncology, Third Affiliated Hospital of Liaoning Medical College, Jinzhou, China;Department of Oncology, First Affiliated Hospital of Liaoning Medical College, Jinzhou, China

关键词: TS gene polymorphism;    Thymidylate synthase;    Pemetrexed treatment;    Non-small cell lung cancer;    Lung adenocarcinoma;   

Others  :  824320
DOI  :  10.1186/1423-0127-20-5

 received in 2012-10-09, accepted in 2013-01-21,  发布年份 2013

【 摘 要 】

Background

Thymidylate synthase (TS) is a key enzyme responsible for DNA synthesis and repair. Altered expression of TS protein or TS gene polymorphisms has been associated with cancer progression and treatment response. This study investigated the expressions of TS and its gene SNPs in non-small cell lung cancer (NSCLC), and then its association with sensitivity to pemetrexed treatment. Immunohistochemistry and qRT-PCR were performed on 160 resected NSCLC specimens and corresponding normal tissues to assess the expressions of TS protein and TS mRNA, and for associations with clinicopathological data. Blood samples of 106 lung adenocarcinoma patients were examined for polymorphisms of the TS gene 3’-UTR 1494del 6 bp, which was then investigated for associations with responses of the patients to pemetrexed treatment and survival.

Results

Expression of both TS protein and its mRNA was elevated in NSCLC tissues compared with matched normal tissues, and significantly higher in lung squamous cell carcinoma than in lung adenocarcinoma. TS expression was associated with poor tumor differentiation. Furthermore, the genotyping data showed that 56% of lung adenocarcinoma patients had the TS gene 3’-UTR 1494 bp (−6 bp/-6 bp) genotype and the rest had TS gene 3’-UTR 1494 bp (−6 bp/+6 bp). There was no TS 3’-UTR 1494 bp (+6 bp/+6 bp) genotype in any patients. Statistical analysis revealed that gender, tumor stage, and TS 3’-UTR 1494del 6 bp polymorphism were significant prognostic factors after short-term pemetrexed treatment. Log-rank analysis revealed that patients with the (−6 bp/-6 bp) genotype had significantly better progression-free and overall survival than patients with (−6 bp/+6 bp).

Conclusions

This study showed that TS protein is highly expressed in NSCLC and that polymorphisms of TS 3’-UTR 1494del 6 bp are associated with sensitivity of lung adenocarcinoma patients to pemetrexed treatment. This suggests that TS gene polymorphisms should be further evaluated as prognostic markers for personalized therapy in lung adenocarcinoma.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011, 364:947-955.
• [3]Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
• [4]Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, et al.: The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010, 69:323-329.
• [5]Scagliotti GV, Ceppi P, Capelletto E, Novello S: Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer 2009, 10(Suppl 1):S35-S40.
• [6]Curtin K, Ulrich CM, Samowitz WS, Bigler J, Caan B, Potter JD, et al.: Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival. Int J Cancer 2007, 120:2226-2232.
• [7]Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, et al.: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006, 24:1883-1891.
• [8]Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000, 9:1381-1385.
• [9]Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, et al.: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006, 24:1603-1611.
• [10]Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, et al.: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004, 14:319-327.
• [11]Zhai X, Gao J, Hu Z, Tang J, Qin J, Wang S, et al.: Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case–control analysis. BMC Cancer 2006, 6:138. BioMed Central Full Text
• [12]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.: New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
• [13]Common Terminology Criteria for Adverse Events v3.0 (CTCAE). August 9, 2006.
• [14]Otake Y, Tanaka F, Yanagihara K, Hitomi S, Okabe H, Fukushima M, et al.: Expression of thymidylate synthase in human non-small cell lung cancer. Jpn J Cancer Res 1999, 90:1248-1253.
• [15]Nakagawa T, Otake Y, Yanagihara K, Miyahara R, Ishikawa S, Fukushima M, et al.: Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004, 43:145-149.
• [16]Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, et al.: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
• [17]Hashimoto H, Ozeki Y, Sato M, Obara K, Matsutani N, Nakagishi Y, et al.: Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006, 106:1595-1601.
• [18]Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF: Polymorphism in the 3′-untranslated region of thymidylate synthase gene and sensitivity of stomach cancer to fluoropymidine-based chemotherapy. J Hum Genet 2006, 51:155-160.
• [19]Gao CM, Takezaki T, Wu JZ, Liu YT, Ding JH, Li SP, et al.: Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking. Asian Pac J Cancer Prev 2004, 5:133-138.
• [20]Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, et al.: Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010, 14(Suppl 1):47-53.
• [21]Hua B, Li M, Shuhang W, et al.: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27(16):2653-2659.